Successful dose reduction of dupilumab in atopic dermatitis
Michael R. Ardern‐Jones, Emily E Buchanan, Samba Njungu, Daniel O’Driscoll
Abstract
Current UK, European and USA atopic dermatitis guidelines do not currently advise on the possibility of dose reduction of dupilumab therapy below the licensed dose of 300 mg subcutaneously every 2 weeks for adults. Here, we report preliminary findings to suggest that in those who respond well to the licensed dose, dupilumab dosing can be reduced while maintaining good disease control. We propose a randomized controlled clinical trial to further analyse the cost effectiveness of this approach.
Topics & Concepts
DupilumabAtopic dermatitisMedicineDosingDermatologyRandomized controlled trialClinical trialReduction (mathematics)Disease controlInternal medicineEnvironmental healthGeometryMathematicsDermatology and Skin DiseasesAllergic Rhinitis and SensitizationAsthma and respiratory diseases